Federal Register / Vol. 60, No. 70 / Wednesday, April 12, 1995 / Notices 18617

for law enforcement purposes.’’ This

exemption permits use of the

information for all law enforcement

purposes, including all police,

prosecutorial, release supervision,

correctional, and judicial uses.

Paragraph (2) in subsection (d) says

that registration information may be

disclosed to government agencies

conducting confidential background

checks. ‘‘Confidential’’ should be

understood to mean a background check

where information is disclosed to an

interested party or parties—such as a

background check conducted by a

government agency that provides

information concerning prospective

employees to public or private

employers—as opposed to release of the

information to the general public.

Release to the public, and other non-law

enforcement, non-background check

uses, are governed by paragraph (3).

Paragraph (3) in subsection (d) says

that the designated state law

enforcement agency, and any local law

enforcement agency authorized by the

state agency, may release relevant

information that is necessary to protect

the public concerning a specific person

required to register under this section.

The Act does not impose any limitations

on the standards and procedures that

states may adopt for determining when

public safety necessitates community

notification. For example, states could

implement this authority by engaging in

particularized determinations that

individual offenders are sufficiently

dangerous to require community

notification concerning the offender’s

presence. Alternatively, states could

make categorical judgments that

protection of the public necessitates

community notification with respect to

all offenders with certain characteristics

or in certain offense categories.

Releases of information for publicprotection purposes short of general

community notification—such as giving

notice about an offender’s location to

the victims of his offenses, or to

agencies or organizations in specified

categories—are also permitted under

paragraph (3).

The language in paragraph (3), like

that in paragraphs (1) and (2), is

permissive, and does not require states

to release information. Paragraph (3)

also does not deprive states of the

authority to exercise centralized control

over the release of information, or if the

state prefers, to generally authorize local

agencies to release information as

necessary. In addition to permitting

proactive community notification and

other notification, as discussed above,

paragraph (3) and other provisions of

the Act do not bar states from making

registration information available upon

request, if it is determined that such

access is necessary for the protection of

the public concerning persons who are

required to register.

A proviso at the end of paragraph (3)

in subsection (d) states that the identity

of the victim of an offense that requires

registration under the Act shall not be

released.

The purpose of this proviso is to

protect the privacy of victims, and its

restrictions may accordingly be waived

at the victim’s options. The proviso only

applies to paragraph (3), and does not

limit the disclosure of victim identity

pursuant to paragraphs (1) and (2),

relating to law enforcement uses and

confidential background checks.

Immunity for Good Faith Conduct—

Subsection (e)

Subsection (e) states that law

enforcement agencies, employees of law

enforcement agencies, and state officials

shall be immune from liability for good

faith conduct under the Act.

Compliance—Subsection (f)

States have three years from the date

of enactment to come into compliance

with the Act unless the Attorney

General grants an additional two years

where a state is making good faith

efforts at implementation. States that

fail to come into compliance within the

specified time period will be subject to

a mandatory 10% reduction of Byrne

Formula Grant funding, and any funds

that are not allocated to noncomplying

states will be reallocated to states that

are in compliance. The reallocated

funds will be distributed among

complying states in proportion to their

populations.

States are encouraged to submit

descriptions of their existing or

proposed registration systems for sex

offenders in conjunction with their

applications for Byrne Formula Grant

funding, even prior to the expiration of

the ‘‘grace period’’ provided by the Act

for achieving compliance. Those

submissions will enable the Department

of Justice to review the status of state

compliance with the Act, and to suggest

any necessary changes to achieve

compliance before the funding

reduction goes into effect.

To maintain eligibility for full Byrne

Formula Grant funding following the

three-year grace period, states will be

required to submit information that

shows compliance with the Act in at

least one program year, or an

explanation of why compliance cannot

be achieved within that period and a

description of good faith efforts that

justify an extension of time (but not

more than two years) for achieving

compliance. States will also be required

to submit information in subsequent

program years concerning any changes

in sex offender registration systems that

may affect compliance with the Act.

Dated: April 7, 1995.

Janet Reno,

Attorney General.

[FR Doc. 95–8966 Filed 4–11–95; 8:45 am]

BILLING CODE 4410–01–M

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Application

Pursuant to § 1301.43(a) of Title 21 of

the Code of Federal Regulations (CFR),

this is notice that on January 30, 1995,

Ganes Chemicals, Inc., Industrial Park

Road, Pennsville, New Jersey 08070,

made application to the Drug

Enforcement Administration (DEA) for

registration as a bulk manufacturer of

the basic classes of controlled

substances listed below:

Drug Schedule

Methylphenidate (1724) ................. II

Amobarbital (2125) ........................ II

Pentobarbital (2270) ...................... II

Secobarbital (2315) ........................ II

Glutethimide (2550) ....................... II

Methadone (9250) .......................... II

Methadone-intermediate (9254) ..... II

Dextropropoxyphene, bulk (nondosage forms) (9273).II

The firm plans to manufacturer the

controlled substances for distribution as

bulk products to its customers.

Any other such applicant and any

person who is presently registered with

DEA to manufacture such substances

may file comments or objections to the

issuance of the above application and

may also file a written request for a

hearing thereon in accordance with 21

CFR 1301.54 and in the form prescribed

by 21 CFR 1316.47.

Any such comments, objections, or

requests for a hearing may be addressed

to the Deputy Assistant Administrator,

Office of Diversion Control, Drug

Enforcement Administration, United

States Department of Justice,

Washington, D.C. 20537, Attention: DEA

Federal Register Representative (CCR),

and must be filed no later than May 12,

1995.
18618 Federal Register / Vol. 60, No. 70 / Wednesday, April 12, 1995 / Notices

Dated: April 4, 1995.

Gene R. Haislip,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 95–8919 Filed 4–11–95; 8:45 am]

BILLING CODE 4410–09–M

Manufacturer of Controlled

Substances; Notice of Application

Pursuant to § 1301.43(a) of Title 21 of

the Code of Federal Regulations (CFR),

this is notice that on December 16, 1994,

Knoll Pharmaceuticals, 30 North

Jefferson Road, Whippany, New Jersey

07981, made application to the Drug

Enforcement Administration (DEA) for

registration as a bulk manufacturer of

the Schedule II controlled substance

Hydromorphone (9150).

The firm plans to produce

Hydromorphone bulk product and

finished dosage units of Dilaudid for

distribution to its customers.

Any other such application and any

person who is presently registered with

DEA to manufacture such substances

may file comments to objections to the

issuance of the above application and

may also file a written request for a

hearing thereon in accordance with 21

CFR 1301.54 and in the form prescribed

by 21 CFR 1316.47.

Any such comments, objections, or

requests for a hearing may be addressed

to the Deputy Assistant Administrator,

Office of Diversion Control, Drug

Enforcement Administration, United

States Department of Justice,

Washington, DC 20537, Attention: DEA

Federal Register Representative (CCR),

and must be filed no later than May 12,

1995.

Dated: April 4, 1995.

Gene R. Haislip,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 95–8918 Filed 4–11–95; 8:45 am]

BILLING CODE @4410–09–M

Manufacturer of Controlled

Substances; Notice of Application

Pursuant to § 1301.43(a) of Title 21 of

the Code of Federal Regulations (CFR),

this is notice that on January 30, 1995,

Mallinckrodt Chemical, Inc.,

Mallinckrodt & Second Streets, St.

Louis, Missouri 63147, made

application to the Drug Enforcement

Administration (DEA) for registration as

a bulk manufacturer of the basic classes

of controlled substances listed below:

Drug Schedule

Tetrahydrocannabinols (7370) ....... I

Methylphenidate (1724) ................. II

Cocaine (9041) .............................. II

Codeine (9050) .............................. II

Diprenorphine (9058) ..................... II

Etorphine Hydrochloride (9059) ..... II

Dihydrocodeine (9120) ................... II

Hydrocodone (9193) ...................... II

Levorphanol (9220) ........................ II

Meperidine (9230) .......................... II

Methadone (9250) .......................... II

Methadone-intermediate (9254) ..... II

Dextropropoxyphene, bulk (nondosage forms) (9273).II

Morphine (9300) ............................. II

Thebaine (9333) ............................. II

Opium extracts (9610) ................... II

Opium fluid extract (9620) ............. II

Opium tincture (9630) .................... II

Opium powdered (9639) ................ II

Opium granulated (9640) ............... II

Oxymorphone (9652) ..................... II

Alfentanil (9737) ............................. II

Sufentanil (9740) ............................ II

Fentanyl (9801) .............................. II

The firm plans to produce bulk

finished products for distribution to its

customers.

Any other such applicant and any

person who is presently registered with

DEA to manufacture such substances

may file comments or objections to the

issuance of the above application and

may also file a written request for a

hearing thereon in accordance with 21

CFR 1301.54 and in the form prescribed

by 21 CFR 1316.47.

Any such comments, objections, or

requests for a hearing may be addressed

to the Deputy Assistant Administrator,

Office of Diversion Control, Drug

Enforcement Administration, United

States Department of Justice,

Washington, D.C. 20537, Attention: DEA

Federal Register Representative (CCR),

and must be filed on later than May 12,

1995.

Dated: April 4, 1995.

Gene R. Haislip,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 95–8920 Filed 4–11–95; 8:45 am]

BILLING CODE 4410–09–M

Manufacturer of Controlled

Substances; Notice of Registration

By Notice dated January 24, 1995, and

published in the Federal Register on

February 6, 1995, (60 FR 7071),

Orpharm, Inc., 728 West 19th Street,

Houston, Texas 77008, made

application to the Drug Enforcement

Administration to be registered as a bulk

manufacturer of the basic classes of

controlled substances listed below:

Drug Schedule

Methadone (9250) .......................... II

Methadone intermediate (9254) ..... II

Levo-alphacetylmethadol (1948) .... II

A comment was filed by a registered

manufacturer in which it was stated that

a hearing would not be requested if the

DEA can determine that Orpharm will

manufacture methadone and

methadone-intermediate solely for the

production of LAAM. The DEA has

determined that this is the case.

Therefore, pursuant to Section 303 of

the Comprehensive Drug Abuse

Prevention and Control Act of 1970 and

Title 21, Code of Federal Regulations,

§ 1301.54(e), the Deputy Assistant

Administrator, Office of Diversion

Control, hereby orders that the

application submitted by the above firm

for registration as a bulk manufacturer

of the basic classes of controlled

substances listed above is granted.

Dated: April 4, 1995.

Gene R. Haislip,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 95–8921 Filed 4–11–95; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF LABOR

Bureau of Labor Statistics

Business Research Advisory Council;

Notice of Meeting and Agenda

The regular Spring meeting of the

Committee on Occupational Safety and

Health Statistics of the Business

Research Advisory Council will be held

on May 4, 1995, at 1:00 p.m. The

meeting will be held in Meeting Room

9 of the Postal Square Building

Conference Center, 2 Massachusetts

Avenue, NE., Washington, DC.

The Business Research Advisory

Council and its committees advise the

Bureau of Labor Statistics with respect

to technical matters associated with the

Bureau’s programs. Membership

consists of technical officers from

American business and industry.

The schedule and agenda for the

meeting is as follows:

Thursday, May 4, 1995

1:00–4:00 p.m.—Committee on

Occupational Safety and Health

Statistics

1. Report on the demographics of

injured/ill workers and the

circumstances of their injuries and

illnesses as reported in the 1993